HDL Proteome and Alzheimer’s Disease: Evidence of a Link
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Several lines of epidemiological evidence link increased levels of high-density lipoprotein-cholesterol (HDL-C) with lower risk of Alzheimer’s disease (AD). This observed relationship might reflect the beneficial effects of HDL on the cardiovascular system, likely due to the implication of vascular dysregulation in AD development. The atheroprotective properties of this lipoprotein are mostly due to its proteome. In particular, apolipoprotein (Apo) A-I, E, and J and the antioxidant accessory protein paraoxonase 1 (PON1), are the main determinants of the biological function of HDL. Intriguingly, these HDL constituent proteins are also present in the brain, either from in situ expression, or derived from the periphery. Growing preclinical evidence suggests that these HDL proteins may prevent the aberrant changes in the brain that characterize AD pathogenesis. In the present review, we summarize and critically examine the current state of knowledge on the role of these atheroprotective HDL-associated proteins in AD pathogenesis and physiopathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 2×
“Two genomic wide association studies (GWAS) have identified the CLU gene as a novel risk factor for late-onset AD [98,99], becoming the third most common genetic risk factor after APOE and bridging integrator 1 (BIN1).”
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425 · cited 3×
“The role of apoE in Aβ processing and deposition is very well known, and has been extensively reviewed elsewhere [58].”
BackgroundInfluentialHDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390 · cited 16×
“In fact, a centenarians study in Ashkenazi Jews revealed that plasma HDL-C levels are positively related with cognitive function, determined by the mini-mental state examination (MMSE), an index of cognitive performance [8].”
BackgroundInfluentialAPOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 2×
“, 2017 [62] In vivo (animal model) ApoE4 worsened the tau-mediated neurodegeneration”
BackgroundSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Recent global trends in the prevalence and incidence of dementia, and survival with dementia
Prince, M., Ali, G.-C., Guerchet, M., Prina, A. M., Albanese, E., & Wu, Y.-T. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0188-8 · Cited by 876
Dysfunctional HDL and atherosclerotic cardiovascular disease
Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.124 · Cited by 822 · cited 3×
“Indeed, the functional properties of HDL, and in particular the capacity of HDL to promote cholesterol efflux from macrophages, the first step of the reverse cholesterol transport, is emerging as a better predictor of CVD and in the majority of the cases independently of plasma levels of HDL-C [18,19].”
BackgroundEvacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
The overlap between vascular disease and Alzheimer’s disease - lessons from pathology
Attems, J., & Jellinger, K. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0206-2 · Cited by 739 · cited 1×
“Additional frequent abnormalities are represented by the presence of neuroinflammation and cerebral vessel disease, with the latter affecting 60–90% of AD patients [3].”
BackgroundBell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 4×
“, 2007 [47] In vivo (animal model) ApoJ contributed to the clearance of Aβ from the brain”
BackgroundInfluentialVerghese, P. B., Castellano, J. M., Garai, K., Wang, Y., Jiang, H., Shah, A., Bu, G., Frieden, C., & Holtzman, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220484110 · Cited by 556
Besler, C., Heinrich, K., Rohrer, L., Doerries, C., Riwanto, M., Shih, D. M., Chroni, A., Yonekawa, K., Stein, S., Schaefer, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42946 · Cited by 535
Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism
Mahley, R. W. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307023 · Cited by 516
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 2×
“Subsequently, a second work from the same group demonstrated that the absence of both apoJ and apoE significantly increased Aβ production and amyloid deposition [111].”
Lipoprotein receptors in the nervous system
Herz, J., & Bock, H. H. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135342 · Cited by 457
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Lynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P. M., Warner, D. S., & Laskowitz, D. T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306923200 · Cited by 394
DeMattos, R. B., O'dell, M. A., Parsadanian, M., Taylor, J. W., Harmony, J. A. K., Bales, K. R., Paul, S. M., Aronow, B. J., & Holtzman, D. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162228299 · Cited by 359
May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., & Finch, C. E. (1990) · Neuron · doi:10.1016/0896-6273(90)90342-d · Cited by 339 · cited 2×
“, 1990 [104] In vivo (animal model) ApoJ concentrations were increased in the AD brain, together with Aβ plaques”
BackgroundMyeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex
Huang, Y., Wu, Z., Riwanto, M., Gao, S., Levison, B. S., Gu, X., Fu, X., Wagner, M. A., Besler, C., Gerstenecker, G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67478 · Cited by 269
HDL and cholesterol handling in the brain
Vitali, C., Wellington, C. L., & Calabresi, L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu148 · Cited by 254 · cited 2×
“Brain cholesterol transport from astrocytes to neurons occurs with astrocyte-secreted apoE that binds cholesterol and phospholipids through an interaction with the membrane transporters ABCA1, ABCG1, and remodeling enzymes [35], generating particles able to interact with the neuronal LDL receptors family, and leading…”
BackgroundNeurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers
Tao, Q., Ang, T. F. A., DeCarli, C., Auerbach, S. H., Devine, S., Stein, T. D., Zhang, X., Massaro, J., Au, R., & Qiu, W. Q. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3597 · Cited by 239 · cited 2×
“In humans, the presence of chronic low-grade inflammation was associated with increased risk of AD, and to shorter latency of disease onset, only in APOE4 carriers [85].”
BackgroundWhat are lipoproteins doing in the brain?
Wang, H., & Eckel, R. H. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.003 · Cited by 234 · cited 1×
“ApoJ is expressed in different tissues, such as the pancreas, lymphoid tissue, testis, prostate, and brain [92], and is present in biological fluids; apoJ is associated with a variety of functions including complement inhibition [91], chaperon function [94], lipid transport [95], and apoptosis [96].”
BackgroundFagan, A. M., Holtzman, D. M., Munson, G., Mathur, T., Schneider, D., Chang, L. K., Getz, G. S., Reardon, C. A., Lukens, J., Shah, J. A., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30001 · Cited by 222
ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes
Rawat, V., Wang, S., Sima, J., Bar, R., Liraz, O., Gundimeda, U., Parekh, T., Chan, J., Johansson, J. O., Tang, C., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1400-19.2019 · Cited by 165 · cited 2×
“Specifically, apoE4 induced trapping of ABCA1 intracellularly, leading to a lower ABCA1-mediated cholesterol efflux and lower Aβ degradation capacity [72].”
BackgroundAPOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1
Tachibana, M., Holm, M.-L., Liu, C.-C., Shinohara, M., Aikawa, T., Oue, H., Yamazaki, Y., Martens, Y. A., Murray, M. E., Sullivan, P. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124853 · Cited by 156
Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease
Wadhwani, A. R., Affaneh, A., Van Gulden, S., & Kessler, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25455 · Cited by 142 · cited 1×
“Mechanistically, apoE4 may induce phosphorylated tau and cell injury through a heparin sulfate proteoglycan-dependent process [64].”
BackgroundKoldamova, R. P., Lefterov, I. M., Lefterova, M. I., & Lazo, J. S. (2001) · Biochemistry · doi:10.1021/bi002186k · Cited by 131 · cited 3×
“In this regard, in vitro evidence suggests that apoA-I interacts with Aβ and prevents its aggregation [40].”
BackgroundInfluentialFung, K. Y., Wang, C., Nyegaard, S., Heit, B., Fairn, G. D., & Lee, W. L. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00841 · Cited by 129 · cited 1×
“One hypothesis is that it would cross the BBB bound to discoidal HDLs, which may enter the CNS via scavenger receptor class B, type I-mediated uptake or other unknown mechanisms [167,168].”
Background25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner
Wong, M. Y., Lewis, M., Doherty, J. J., Shi, Y., Cashikar, A. G., Amelianchik, A., Tymchuk, S., Sullivan, P. M., Qian, M., Covey, D. F., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01869-3 · Cited by 121 · cited 1×
“2020 [82] In vitro Increased secretion of IL-1β secretion in apoE4compared with apoE3-expressing microglia”
BackgroundHDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114 · cited 4×
“Some intriguing hypothesis on the role of HDL and its associated proteins in brain function and their influence on neurodegeneration, have also been formulated [5,32,33].”
BackgroundResultInfluentialNilselid, A.-M., Davidsson, P., Nägga, K., Andreasen, N., Fredman, P., & Blennow, K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.12.005 · Cited by 104 · cited 1×
“Furthermore, apoJ concentrations were also higher in the hippocampus and cortex of the AD brain together with Aβ plaques [104], and this also occurred in the CSF [105].”
BackgroundDi Domenico, F., Pupo, G., Giraldo, E., Badìa, M.-C., Monllor, P., Lloret, A., Eugenia Schininà, M., Giorgi, A., Cini, C., Tramutola, A., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.004 · Cited by 97
O’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
Minagawa, H., Gong, J., Jung, C., Watanabe, A., Lund‐Katz, S., Phillips, M. C., Saito, H., & Michikawa, M. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22073 · Cited by 90 · cited 1×
“Lipidation of apoE is mediated by ABCA1 activity and, in this regard, cholesterol efflux from apoE4and ABCA1-expressing astrocytes was lower compared to the efflux from apoE3-expressing cells [71].”
ResultApolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3
Rebeck, G. W., Kindy, M., & LaDu, M. J. (2002) · Journal of Alzheimer's Disease · doi:10.3233/jad-2002-4304 · Cited by 89 · cited 1×
“Specifically, the APOE4 allele is widely known to be one of the strongest risk factors for developing AD [54], while APOE2 has shown neuroprotective effects [55].”
BackgroundYassine, H. N., Feng, Q., Chiang, J., Petrosspour, L. M., Fonteh, A. N., Chui, H. C., & Harrington, M. G. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002886 · Cited by 80
Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease
Zimetti, F., Caffarra, P., Ronda, N., Favari, E., Adorni, M. P., Zanotti, I., Bernini, F., Barocco, F., Spallazzi, M., Galimberti, D., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160411 · Cited by 75
Self-citationApolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid
Heinsinger, N. M., Gachechiladze, M. A., & Rebeck, G. W. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw067 · Cited by 74
Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69 · cited 1×
“Some intriguing hypothesis on the role of HDL and its associated proteins in brain function and their influence on neurodegeneration, have also been formulated [5,32,33].”
BackgroundMerino-Zamorano, C., Fernández-de Retana, S., Montañola, A., Batlle, A., Saint-Pol, J., Mysiorek, C., Gosselet, F., Montaner, J., & Hernández-Guillamon, M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150976 · Cited by 63 · cited 1×
“This passage decreased when the LRP1/LRP2 pathway was blocked [116], suggesting that the relationship between apoJ and Aβ might be relevant for amyloid clearance in vivo.”
BackgroundAlterations in cholesterol metabolism–related genes in sporadic Alzheimer's disease
Picard, C., Julien, C., Frappier, J., Miron, J., Théroux, L., Dea, D., Breitner, J. C. S., & Poirier, J. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.018 · Cited by 60 · cited 1×
“Recent findings obtained using an in vitro BBB model of primary cerebral endothelial cells, cultured on trans-wells to mimic the trafficking between the basolateral [115] and apical (blood) compartments, showed that the transport of labelled fluorescent Aβ from the basolateral to apical compartment was increased when…”
BackgroundPicard, C., Poirier, A., Bélanger, S., Labonté, A., Auld, D., Poirier, J., & on behalf of the PREVENT-AD Research Group (2019) · PLOS ONE · doi:10.1371/journal.pone.0220254 · Cited by 59 · cited 7×
“For example, the proprotein convertase subtilisin/kexin type 9 (PCSK9), very well known for its regulating effect on plasma lipids [75], seems to promote the degradation of the apoE-receptors in the brain [76].”
BackgroundInfluentialOrth, M., Weng, W., Funke, H., Steinmetz, A., Assmann, G., Nauck, M., Dierkes, J., Ambrosch, A., Weisgraber, K. H., Mahley, R. W., et al. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1306 · Cited by 42 · cited 10×
“This mechanism would explain the observations made in postmortem human AD brains, where the positive correlation between LRP1 and Aβ levels was strengthened by the presence of the APOE4 allele [61].”
BackgroundInfluentialDecreased serum arylesterase activity in autism spectrum disorders
Gaita, L., Manzi, B., Sacco, R., Lintas, C., Altieri, L., Lombardi, F., Pawlowski, T. L., Redman, M., Craig, D. W., Huentelman, M. J., et al. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.04.010 · Cited by 39
Self-citationArunsak, B., Pratchayasakul, W., Amput, P., Chattipakorn, K., Tosukhowong, T., Kerdphoo, S., Jaiwongkum, T., Thonusin, C., Palee, S., Chattipakorn, N., et al. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108470 · Cited by 19 · cited 1×
“Supporting this hypothesis, the administration of a small molecule, inhibiting PCSK9, restored BBB proteins in the hippocampus, and decreased cognitive impairment in rats [80].”
Background
Cited by
Reading, C. L., Ahlem, C. N., & Murphy, M. F. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0022 · Cited by 84
Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
Turri, M., Marchi, C., Adorni, M. P., Calabresi, L., & Zimetti, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159123 · Cited by 54
Self-citationZimetti, F., Adorni, M. P., Marsillach, J., Marchi, C., Trentini, A., Valacchi, G., & Cervellati, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6695796 · Cited by 49
Self-citationZuin, M., Cervellati, C., Trentini, A., Passaro, A., Rosta, V., Zimetti, F., & Zuliani, G. (2021) · Diagnostics · doi:10.3390/diagnostics11060984 · Cited by 45
“Indeed, Apo A-I has been demonstrated to cross the BBB through a transcytosis process [14] independent of clathrin, but mediated by the HDL receptor SR-BI [31], or, alternatively, through an involvement of the LDL receptor-related protein family [32].”
BackgroundInfluentialSelf-citationBorràs, C., Mercer, A., Sirisi, S., Alcolea, D., Escolà-Gil, J. C., Blanco-Vaca, F., & Tondo, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169356 · Cited by 39
Metadata
- Authors
- Marsillach, J., Adorni, M. P., Zimetti, F., Papotti, B., Zuliani, G., & Cervellati, C.
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2020-12-03
- Volume
- 9
- Issue
- 12
- Pages
- 1224
- ISSN
- 2076-3921 (ISSN-L)
- OpenAlex
- W3109695053
- Cited by
- 54
- References
- 49
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.